Boothbay Fund Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Boothbay Fund Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$68.5K	Hold	277,311	–	–	﹤0.01%	1903
2025 Q4	$116K	Sell	277,311 -75,981	-22%	-$40.3K	﹤0.01%	1726
2025 Q3	$238K	Buy	353,292 +34,473	+11%	+$18.6K	﹤0.01%	1572
2025 Q2	$173K	Sell	318,819 -218,400	-41%	-$130K	﹤0.01%	1268
2025 Q1	$352K	Hold	537,219	–	–	0.01%	990
2024 Q4	$548K	Buy	+537,219	New	+$982K	0.01%	835
2020 Q2	–	Sell	-11,100	Closed	-$71K	–	1095
2020 Q1	$71K	Buy	+11,100	New	+$82.4K	0.01%	765
2018 Q3	–	Sell	-25,600	Closed	-$364K	–	931
2018 Q2	$364K	Buy	+25,600	New	+$425K	0.03%	419

Other funds holding SGMO

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Boothbay Fund Management's SGMO Position: Q1 2026 in Review

Boothbay Fund Management held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 277,311 shares worth $68.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1903.

Boothbay Fund Management first reported a position in SGMO in Q2 2018 and has held it in 8 quarters since. The position peaked at $548K in Q4 2024. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

Boothbay Fund Management held 277,311 shares of SANGAMO THERAPEUTICS INC worth $68.5K as of Q1 2026.
Boothbay Fund Management left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
SANGAMO THERAPEUTICS INC made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1903 holding.
Boothbay Fund Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2018 and has held it in 8 quarters since.
Boothbay Fund Management's SANGAMO THERAPEUTICS INC position peaked at $548K in Q4 2024.
112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.